SubcutAte / Ascension Healthcare - LARVOL DELTA

Newly added product (Pro Bono Bio Press Release)

Pipeline update • Hemophilia

Business update and change of name from Pro Bono Bio (GlobeNewswire) - "SelectAte Phase II clinical development programme initiated to evaluate the Company’s wholly-owned PEGLip technology in providing prophylactic Factor VIII (FVIII) treatment to haemophilia A (HA) patients with inhibitors to FVIII. Top-line results are expected during 2019….Two pre-clinical programmes initiated to prepare for Phase II clinical trials readiness, targeting (i) prophylactic FVIII treatment of HA patients subcutaneously (SubcutAte programme) and (ii) therapy for patients who, although not currently treated prophylactically, have moderate FVIII deficiency (ChapAte programme).”"

P2 data • Preclinical • Trial status